In exploratory secondary analyses of pooled aducanumab phase 3 participants (ENGAGE/EMERGE) in the amyloid PET substudy, treatment-related amyloid clearance at week 78 was associated with less clinical decline at weeks 78 and 134 and at EMBARK baseline than non-clearance.
RCT
Pang et al. Longitudinal clinical outcomes after amyloid clearance in aducanumab phase 3 studies